Full-Time

Senior Change Manager

Posted on 5/9/2025

Deadline 5/23/25
AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Senior

Mississauga, ON, Canada

Employees are required to work in the office 3 days a week.

Category
Management Consulting
Consulting
Required Skills
Customer Service
Requirements
  • Bachelor’s degree or equivalent
  • Minimum of 5 years’ experience in medium-complexity project management, change management, business or technology consulting
Responsibilities
  • Manage functional projects that are medium complexity and risk and have a mature and supportive partner organisation. Define, implement, and drive project governance across a mature and supportive partner landscape.
  • Cultivate a culture of innovation and continuous improvement within projects and the team, actively seeking opportunities to enhance services and drive efficiency.
  • Develop tailored change management strategies that consider the client’s environment, stakeholder needs, and desired future state. Implement cross-functional, change initiatives that experience some ambiguity in mobilizing. Develop the analysis of change impacts and stakeholder effects resulting from transformation initiatives.
  • Apply effective problem-solving techniques, simplify complex information to create actionable insights.
  • Deliver excellent customer service, effective communication, professionalism and a commitment to exceeding expectations.
  • Ensure that the services provided meet the encouraged standards of quality and deliver value to the organization.
  • Provide guidance and support to junior team members, fostering their professional growth and development.
Desired Qualifications
  • Graduate degree with a minimum of 6+ years of relevant project/change management or consulting experience within medium-complexity programs
  • Pharmaceutical or equivalent global organization experience
  • Certifications: PMI, PMI Agile Practitioner, PMP, PRINCE2 Practitioner, PROSCI Change Management, ACMP CCMP, or similar

AstraZeneca focuses on discovering, developing, and selling prescription medicines. The company specializes in three main areas: Oncology, which deals with cancer treatment; Cardiovascular, Renal & Metabolism, which addresses heart, kidney, and metabolic diseases; and Respiratory & Immunology, which targets lung and immune system diseases. Their products are developed through extensive research and development, followed by rigorous clinical trials and regulatory approvals before reaching the market. AstraZeneca differentiates itself from competitors by investing heavily in scientific research and forming strategic partnerships to enhance drug discovery. Their goal is to advance healthcare by providing effective treatments for serious diseases while collaborating with the scientific community to improve their research capabilities.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • New manufacturing facilities boost AstraZeneca's production capacity and supply chain resilience.
  • AstraZeneca's robust oncology pipeline reinforces its leadership in cancer care.
  • Strategic leadership moves may enhance research and development capabilities.

What critics are saying

  • Increased competition in oncology may impact AstraZeneca's market share.
  • Stricter regulatory scrutiny could delay drug approval processes.
  • Rising raw material costs may affect production costs and profit margins.

What makes AstraZeneca unique

  • AstraZeneca's AI collaboration enhances drug discovery efficiency and accuracy.
  • The EsoBiotec acquisition positions AstraZeneca as a leader in innovative cell therapies.
  • AstraZeneca's A.Catalyst Network fosters global collaboration and innovation in healthcare.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Silicon Canals
May 22nd, 2025
Aptar Digital Health Announces Licensing Agreement With AstraZeneca to Develop AI-Powered Screening Algorithms

Aptar Digital Health announces licensing agreement with AstraZeneca to develop ai-powered screening algorithms.

HC Data
May 21st, 2025
AstraZeneca Marks Seventh Consecutive Year of Plenary Data at ASCO, Advancing Breast and Gastric Cancer Care

AstraZeneca will present new data from over 80 abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3), underscoring its leadership in oncology through a diverse and robust pipeline.

Cision
May 21st, 2025
Director Declaration

21 May 2025Director DeclarationAstraZeneca PLC (the Company) today announced that Pascal Soriot, Chief Executive Officer of the Company, has been appointed a director of Agilent Technologies Inc. with effect from 21 May 2025.This announcement is made pursuant to Listing Rule 6.4.9 (2).AstraZenecaAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZenecaContactsFor details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.Matthew BowdenCompany SecretaryAstraZeneca PLCThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom

Clinical Trials Arena
May 20th, 2025
ATS 2025: Tozorakimab's safety reinforced with positive results from FRONTIER studies

On 18 May at the 2025 American Thoracic Society (ATS) International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its FRONTIER programmes, which are a series of four Phase II clinical trials.

Cision
May 20th, 2025
Acquisition Of Esobiotec Completed

20 May 2025 Acquisition of EsoBiotec completed AstraZeneca today announced the successful completion of the acquisition (https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-acquire-esobiotec.html) of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to transformative cell therapy treatments delivered in just minutes rather than the current

INACTIVE